Similar articles

• Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.

  Frampton JE, Faulds D. Frampton JE, et al. Pharmacoeconomics. 1996 Jan;9(1):76-96. doi: 10.2165/00019053-199609010-00008. Pharmacoeconomics. 1996. PMID: 10161371
• Hematopoietic growth factors for chemotherapy-induced neutropenia.

  Yalçin S. Yalçin S. Cancer Invest. 1999;17(7):555-6. doi: 10.3109/07357909909032867. Cancer Invest. 1999. PMID: 10518202 No abstract available.
• Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.

  Bhana N. Bhana N. Curr Opin Oncol. 2007 Jul;19(4):328-35. doi: 10.1097/01.cco.0000275309.58868.11. Curr Opin Oncol. 2007. PMID: 17545795 Review.
• G-CSF: filgrastim, lenograstim and biosimilars.

  Welte K. Welte K. Expert Opin Biol Ther. 2014 Jul;14(7):983-93. doi: 10.1517/14712598.2014.905537. Epub 2014 Apr 7. Expert Opin Biol Ther. 2014. PMID: 24707817 Review.
• [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].

  Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G. Sehouli J, et al. Dtsch Med Wochenschr. 2010 Mar;135(9):385-9. doi: 10.1055/s-0030-1249174. Epub 2010 Feb 23. Dtsch Med Wochenschr. 2010. PMID: 20180162 German.